Media ReleasesImpediMed

View All ImpediMed News


ImpediMed - Appendix 4E


ImpediMed Limited (ASX.IPD) today released its Appendix 4E – Preliminary Final Report for the financial year ended 30 June 2021 (FY’21).

Revenue Summary:

• SOZO Revenue grew by 64% to $7.6 million (30 June 2020: $4.7 million)
• Total Revenue grew by 46% to $8.4 million (30 June 2020: $5.7 million)
• SOZO SaaS Revenuei grew by 77% to $6.0 million (30 June 2020: $3.4 million)
-- SOZO SaaS Revenue of $4.2 million from Core Businessii (30 June 2020: $3.4 million).
-- SOZO SaaS Revenue of $1.9 million from Clinical Businessiii (30 June 2020: nil).

For more information, download the attached PDF.

Download this document

Are you a 708 sophisticated investor?

A sophisticated investor is defined under Section 708 of the Corporations Act (net assets of $2.5 million or annual incomes in excess of $250,000).

They are eligible to receive information regarding wholesale investment opportunities that are not available to regular or retail investors.

Please subscribe if you would like to be alerted to these types of opportunities.